TAT and influenza: We hypothesized that in mice and CR challenged with LPS or infected with influenza, treatment with our engineered vectors, “AdV.C3-Tat/HIV-Box ASer” or “AdV.C3-Tat/HIV-Box AGly,” would produce rBox A to mitigate ALI by antagonizing TLR4-mediated inflammation induced by HMGB1, while “AdV.C3-Tat/HIV-Luc” would secrete luciferase and serve as a negative control.